Induction of Peptide-specific CTL Activity and Inhibition of Tumor Growth Following Immunization with Nanoparticles Coated with Tumor Peptide-MHC-I Complexes

Viruses
Nanomedicine
/References

Kim, Sang-Hyun, Ha-Eun Park, Seong-Un Jeong, Jun-Hyeok Moon, Young-Ran Lee, Jeong-Ki Kim, Hyunseok Kong, Chan-Su Park, and Chong-Kil Lee. 2021. “Induction of Peptide-Specific CTL Activity and Inhibition of Tumor Growth Following Immunization with Nanoparticles Coated with Tumor Peptide-MHC-I Complexes.” Immune Network 21 (6). https://doi.org/10.4110/in.2021.21.e44.

Tumor peptides associated with MHC class I molecules or their synthetic variants have attracted great attention for their potential use as vaccines to induce tumor-specific CTLs. However, the outcome of clinical trials of peptide-based tumor vaccines has been disappointing. There are various reasons for this lack of success, such as difficulties in delivering the peptides specifically to professional Ag-presenting cells, short peptide half-life in vivo, and limited peptide immunogenicity. We report here a novel peptide vaccination strategy that efficiently induces peptide-specific CTLs. Nanoparticles (NPs) were fabricated from a biodegradable polymer, poly(D,L-lactic-co-glycolic acid), attached to H-2Kb molecules, and then the natural peptide epitopes associated with the H-2Kb molecules were exchanged with a model tumor peptide, SIINFEKL (OVA257-268). These NPs were efficiently phagocytosed by immature dendritic cells (DCs), inducing DC maturation and activation. In addition, the DCs that phagocytosed SIINFEKL-pulsed NPs potently activated SIINFEKL-H-2Kb complex-specific CD8+ T cells via cross-presentation of SIINFEKL. In vivo studies showed that intravenous administration of SIINFEKL-pulsed NPs effectively generated SIINFEKL-specific CD8+ T cells in both normal and tumor-bearing mice. Furthermore, intravenous administration of SIINFEKL-pulsed NPs into EG7.OVA tumor-bearing mice almost completely inhibited the tumor growth. These results demonstrate that vaccination with polymeric NPs coated with tumor peptide-MHC-I complexes is a novel strategy for efficient induction of tumor-specific CTLs.

View full article

Recent Publications

Surfactant-shell lipid nanocapsules (LNCs) are promising skin delivery systems. They are composed of an oily core with a stabilising shell of surfactant and phosphatidylcholine. LNCs’ hydrodynamic diameter can be easily tuned by varying the surfactant content in the formulation. Hydrophilic surfactants incorporated into LNCs have shown toxicity in mammalian cells. To date, the toxicity of all published surfactant-shelled LNCs produced by the the phase inverson temperature (PIT) method has been investigated using hydrophilic surfactants, with no studies examining the impact of incorporating hydrophobic surfactants on LNCs’ in vitro behaviour. Span 80 is a hydrophobic surfactant and has been extensively used in manufacturing various ranges of nanoparticles. The present study formulated Span 80-containing LNCs to evaluate their in vitro behaviour in the B16F10 melanoma cell line. LNC-100-S8 of Kolliphor HS15/Span 80 (65/35 w/w%) and original LNC100-0 LNCs of Kolliphor HS15 with a hydrodynamic diameter of 100 nm were prepared using the PIT method. A salt aggregation test confirmed increased surface hydrophobicity of LNC100-S8 compared to LNC100-0. Cytotoxicity assays demonstrated that LNC100-S8 had a three-fold lower cytotoxicity than LNC100-0 (IC80 = 11757 μg/mL vs 3184 μg/mL). Flow cytometry analysis indicated significantly higher cellular uptake of LNC100-S8 compared to LNC100-0, with 1.52-fold, 1.46-fold, and 1.67-fold increase at 1 h, 3 h, and 24 h, respectively . Mechanistic investigations revealed that LNC100-S8 uptake predominantly occured via phosphoinositide 3-kinase (PI3K)-regulated macropinocytosis and actin-dependent endocytosis, whereas LNC100-0 also utilised Na+/H+ exchanger-mediated macropinocytosis. Furthermore, protein corona analysis demonstrated increased interactions between LNC100-S8 and B16F10-conditioned media proteins, leading to bimodal size distribution and elevated polydispersity index (>0.3), which influenced their endocytic pathways. Overall, Our findings revealed the high promise of our Span 80-containing LNCs as a drug delivery system with enhanced cellular uptake and biocompatibility in B16F10 melanoma cells compared to conventional LNCs composed of Kolliphor HS15 surfactant, highlighting their potential uses in topical delivery to melanoma and other skin diseases.

2025
No items found.